Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus SERPASIL APRESOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus SERPASIL APRESOLINE.
ALDORIL 25 vs SERPASIL-APRESOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases cGMP via NO).
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Reserpine: ~50-100 hours (biphasic; terminal phase 4.5-11 days due to enterohepatic circulation and tissue binding). Hydralazine: 2-8 hours (rapid acetylators 30-50 min, slow acetylators 2-8 hours); longer in renal impairment.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Reserpine: <1% unchanged in urine; extensive hepatic metabolism followed by renal and fecal excretion. Hydralazine: 80-90% renal; 10% fecal; 1-2% unchanged in urine; polymorphic acetylation (rapid/slow acetylators) affects clearance.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination